To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Precigen (NasdaqGS:PGEN) Q4 2025 Earnings call March 25, 2026 04:30 PM ET Company ParticipantsHarry Thomasian Jr. - CFOHelen Sabzevari - President and CEOJason Butler - Managing Director of Biotechnology Equity ResearhMichael DiFiore - Managing DirectorPhil Tennant - Chief Commercial OfficerRútul R. Shah - COOSteven Harasym - VP of Investor RelationsConference Call ParticipantsBrian Chung - Investment Risk AnalystSwayampakula Ramakanth - Managing Director and Senior Equity AnalystOperatorThis call is being ...

Precigen (NasdaqGS:PGEN) Q4 2025 Earnings call March 25, 2026 04:30 PM ET Company ParticipantsHarry Thomasian Jr. - CFOHelen Sabzevari - President and CEOJason Butler - Managing Director of Biotechnology Equity ResearhMichael DiFiore - Managing DirectorPhil Tennant - Chief Commercial OfficerRútul R. Shah - COOSteven Harasym - VP of Investor RelationsConference Call ParticipantsBrian Chung - Investment Risk AnalystSwayampakula Ramakanth - Managing Director and Senior Equity AnalystOperatorThis call is being ...

Precigen (NasdaqGS:PGEN) Q4 2025 Earnings call March 25, 2026 04:30 PM ET Speaker5This call is being recorded on Wednesday, March 25, 2026. I would now like to turn the conference over to Steven Harasym. Please go ahead.Speaker8Thank you, operator, and thank you to all those joining us for our fourth quarter and year-end 2025 update call. Joining me today are Helen Sabzevari, our President and CEO, Phil Tennant, our Chief Commercial Officer, and Harry Thomasian Jr., our CFO. Before we begin our prepared rem ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: Securities registered pursuant to Section 12(b) of the Act: 001-36042 PRECIGEN, INC. (Exact name of registrant as specified in i ...

Exhibit 99.1 Precigen Reports Full Year 2025 Financial Results and Business Updates bill government and commercial insurers for physician-administered therapies. Assignment of a permanent J-code streamlines claims processing and will likely facilitate broader patient access. PRGN-2009 AdenoVerse Immunotherapy in HPV-associated cancers GERMANTOWN, MD, March 25, 2026 – Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines ...

Precigen Reports Full Year 2025 Financial Results and Business Updates Accessibility StatementSkip Navigation GERMANTOWN, Md., March 25, 2026 /PRNewswire/ -- Precigen, Inc.(Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced full year 2025 financial results and business updates. "With the FDA approval and launch of PAPZIMEOS, 2025 marked a transformational year for Precigen as we trans ...

Core Insights - Precigen, Inc. will announce its full year 2025 financial results and provide business updates on March 25, 2026, with a conference call scheduled for 4:30 PM ET [1] Company Overview - Precigen is a commercial-stage biopharmaceutical company focused on innovative precision medicines aimed at improving patient lives, particularly in difficult-to-treat diseases with high unmet needs [1] - The company is committed to advancing scientific breakthroughs from proof-of-concept through commercialization, developing a robust pipeline in immuno-oncology, autoimmune disorders, and infectious diseases [1] Upcoming Events - The conference call for discussing the financial results will be accessible via specific phone numbers for North America and international participants, with a recommendation to dial in 10-15 minutes early [1]

Group 1 - Patient Opportunity Equity Strategy achieved a return of 5.99% net of fees in Q4 2025, outperforming the S&P 500 Index which returned 2.65% [1] - The overall market experienced a strong year with a return of 17.9%, marking the seventh-best three-year period in market history [1] - The strategy outperformed the S&P 500 for the third consecutive year with a total return of 26.1% [1] Group 2 - Precigen, Inc. (NASDAQ:PGEN) was highlighted as a leading contributor to the strategy, focusing on gene and cell therapies in immuno-oncology, autoimmune disorders, and infectious diseases [2] - As of March 04, 2026, Precigen, Inc. had a stock price of $3.55 per share, with a one-month return of -16.27% and a 52-week gain of 89.84% [2] - Precigen, Inc. has a market capitalization of $1.256 billion [2] Group 3 - Precigen, Inc. received early approval for Papziemos, the first-in-class "off-the-shelf" immunotherapy for recurrent respiratory papillomatosis (RRP), which is significant for patients with no other treatment options [3] - The company is moving quickly to launch Papziemos, which may lead to self-funding and advancement of other pipeline assets [3] - Dr. Helen Sabzevari, leading the company, has a strong background in immunotherapy and is expected to drive progress in other pipeline assets currently in development [3]

Core Insights - Precigen (PGEN) stock has increased by 185% since early July, primarily due to the FDA approval of its lead asset for Recurrent Respiratory Papillomatosis (RRP) [1] Company Summary - Precigen has received FDA approval for its leading product, which is expected to significantly impact its market position and growth potential [1]